See the DrugPatentWatch profile for Fulvestrant
What is fulvestrant?
Fulvestrant (brand name Faslodex) is a hormone therapy used to treat certain types of breast cancer that are driven by estrogen. It works by blocking estrogen signaling and reducing the amount of estrogen receptor inside cancer cells [1].
How is fulvestrant given?
Fulvestrant is given as an injection by a healthcare professional [1]. The dosing schedule and injection frequency depend on the treatment setting and the patient’s regimen [1].
What breast cancers does fulvestrant treat?
Fulvestrant is used for estrogen receptor–positive breast cancer in specific clinical scenarios, including postmenopausal patients and others depending on menopausal status and prior treatments [1].
How does fulvestrant differ from other hormone therapies?
Fulvestrant is a selective estrogen receptor degrader (SERD), meaning it targets the estrogen receptor for degradation rather than just blocking it. This is different from other endocrine therapies (such as some estrogen receptor blockers) that act by preventing estrogen receptor signaling [1].
Common side effects patients ask about
Side effects can include injection-site reactions and typical endocrine-therapy related symptoms, such as hot flashes and nausea. The exact side-effect profile varies by patient and treatment context [1].
Who should not take it (or who needs extra caution)?
Because fulvestrant is used in hormone receptor–positive breast cancer, eligibility depends on cancer subtype and prior treatment history. Safety and suitability also depend on a patient’s overall condition and other medical factors determined by the treating clinician [1].
How long does it take to work?
Clinical benefit is assessed over treatment cycles, with response evaluated by the treating oncology team using imaging and other measures. The timing can differ across patients and cancer settings [1].
What brand or approvals exist?
Fulvestrant is sold under the brand name Faslodex and is listed by major medical references for breast cancer use in appropriate patient populations [1].
---
Sources
[1] https://www.mayoclinic.org/drugs-supplements/fulvestrant-subcutaneous-route/proper-use/drg-20069042